INT144416

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2007
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 5
Total Number 8
Disease Relevance 4.97
Pain Relevance 0.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (Egfr) cell morphogenesis (Egfr) intracellular (Egfr)
enzyme binding (Egfr) cytoplasm (Egfr) signal transducer activity (Egfr)
Anatomy Link Frequency
brain 1
astrocytes 1
hearts 1
Egfr (Rattus norvegicus)
Pain Link Frequency Relevance Heat
COX2 1 99.20 Very High Very High Very High
ischemia 3 98.82 Very High Very High Very High
cINOD 1 96.60 Very High Very High Very High
Spinal cord 4 91.84 High High
COX-2 inhibitor 1 84.84 Quite High
metalloproteinase 2 82.72 Quite High
Enkephalin 1 78.72 Quite High
agonist 2 77.52 Quite High
opioid receptor 2 77.20 Quite High
Inflammation 43 71.48 Quite High
Disease Link Frequency Relevance Heat
Cancer 175 99.98 Very High Very High Very High
Cv Unclassified Under Development 4 98.82 Very High Very High Very High
Colon Cancer 28 98.72 Very High Very High Very High
Disease 3 97.64 Very High Very High Very High
INFLAMMATION 32 95.88 Very High Very High Very High
Solid Tumor 6 94.28 High High
Cicatrix 1 93.80 High High
Lung Cancer 3 92.04 High High
Frailty 4 91.84 High High
Apoptosis 6 91.48 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
One class of agents that is currently used to target EGFR in the treatment of metastatic CRC (mCRC) is the monoclonal antibodies (MoAbs), which compete with endogenous ligands, including EGF and TGF-?
Regulation (target) of EGFR associated with colon cancer
1) Confidence 0.57 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 0.90 Pain Relevance 0
Blocking a novel Nogo receptor interacting mechanism and/or effects of EGFR inhibition on astrocytes may underlie these effects.
Regulation (effects) of EGFR in astrocytes
2) Confidence 0.45 Published 2007 Journal J. Neurosci. Section Abstract Doc Link 17567803 Disease Relevance 0.41 Pain Relevance 0.15
As KRAS mutation status has been shown to be a predictor of tumor response to anti-EGFR treatment, the EVEREST trial sought to determine whether dose escalation would also be able to induce a response in patients with KRAS mutations.
Regulation (response) of anti-EGFR associated with cancer
3) Confidence 0.42 Published 2010 Journal Current Oncology Section Body Doc Link PMC2901793 Disease Relevance 1.11 Pain Relevance 0
We therefore tested whether DADLE at reperfusion could protect isolated rabbit hearts subjected to 30 min of regional ischemia and 120 min of reperfusion and whether this protection is dependent on Akt, ERK, and EGFR.
Spec (whether) Regulation (dependent) of EGFR in hearts associated with ischemia
4) Confidence 0.26 Published 2007 Journal Am. J. Physiol. Heart Circ. Physiol. Section Abstract Doc Link 17545478 Disease Relevance 0.33 Pain Relevance 0.40
Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
Regulation (modulates) of epidermal growth factor receptor associated with cox2
5) Confidence 0.25 Published 2007 Journal Clin. Cancer Res. Section Title Doc Link 17908994 Disease Relevance 0.19 Pain Relevance 0.19
One class of agents that is currently used to target EGFR in the treatment of metastatic CRC (mCRC) is the monoclonal antibodies.
Regulation (target) of EGFR associated with colon cancer
6) Confidence 0.25 Published 2010 Journal Current Oncology Section Abstract Doc Link PMC2901793 Disease Relevance 0.56 Pain Relevance 0
For example, numerous genes for proteins, such as kinases and phosphatases, that regulate cell signaling were stimulated, whereas the epidermal growth factor receptor gene was down-regulated.
Regulation (regulated) of epidermal growth factor receptor gene
7) Confidence 0.19 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2199289 Disease Relevance 0.13 Pain Relevance 0.10
It is to note that PTK787 treated tumors showed lower normalized values of VEGFR2 and EGFR both at the periphery and central parts of the tumors compared to that of corresponding contralateral brain; whereas vehicle treated tumors did not show any changes in the normalized values of VEGFR2 and EGFR compared to that of corresponding contralateral brain.


Regulation (values) of EGFR in brain associated with cancer
8) Confidence 0.06 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2806917 Disease Relevance 1.34 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox